Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2361-71. eCollection 2014.

Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma.

Author information

1
Department of Radiation Oncology, Qilu Hospital of Shandong University Jinan, China ; Department of Radiation Oncology, Cancer Hospital, General Hospital of Ningxia Medical University Yinchuan, China.
2
Department of Oncology, Wendeng Central Hospital Weihai, China.
3
Department of Digestive Disease, General Hospital of Ningxia Medical University Yinchuan, China.
4
Department of Radiation Oncology, Qilu Hospital of Shandong University Jinan, China.
5
Department of Pathology, Medical College of Shandong University Jinan, Shandong, China.

Abstract

BACKGROUD AND AIM:

Podoplanin (D2-40) is a specific marker for lymphatic endothelium. The vast majority of previous studies on podoplanin immunostaining in esophageal squamous cell carcinoma (ESCC) focused on identifying lymphatic vessel invasion (LVI) and counting lymphatic vessel density (LVD) and had contradictory results. Recent studies show podoplanin expression on cancer cells or tumor stroma in several cancers, which have specific significance; but the status in ESCC remains unclear. Therefore, the aim of this study was to further study and summarize the clinicopathological significance of podoplanin immunoreactivity in ESCC.

MATERIALS AND METHODS:

We examined podoplanin expression in tissue specimens from 107 patients with ESCC by immunohistochemistry. Podoplanin positive lymphatic vessels in intratumoral and peritumoral tissues and podoplanin positive expression in cancer cells and tumor stroma were analyzed, and correlated with clinicopathologic parameters and three-year overall and free-disease survival.

RESULTS:

34 (31.8%) and 28 (26.2%) of 107 specimens had podoplanin positive expression in cancer cells and tumor stroma, respectively. Logistic regression analysis showed high intratumoral lymphatic vessel density (I-LVD) and podoplanin positivity in cancer cells were increased risks of lymph node metastasis (LNM) (OR=2.45, P=0.03; OR=0.35, P=0.01, respectively). Survival analysis showed that I-LVD was a significant factor related to poor three-year overall and free-disease survival (P=0.04, P=0.03, respectively).

CONCLUSIONS:

Previous data and our results show that podoplanin seems to be a useful marker to predict LNM, recurrence, and worse prognosis in ESCC; in particular, LVI, high I-LVD, and podoplanin positivity in cancer cells are associated with LNM, recurrence and overall survival.

KEYWORDS:

Podoplanin; esophagus; immunohistochemistry; squamous cell carcinoma

PMID:
24966946
PMCID:
PMC4069902
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center